Publications
140
Citations
7,372
Est. group size
~5
Recurring co-author estimate
Active years
29
Publishing since 1998
Kathrin Meyer's research focuses on developing gene therapies, particularly using AAV9 viral vectors, to treat rare genetic neuromuscular and neurodevelopmental disorders such as SMARD1/CMT2S, CLN3 disease, FOXG1 syndrome, Rett syndrome, and mitochondrial and GPI-deficiency disorders. The work spans preclinical animal models, vector optimization for safety and efficacy, and translational questions like immune response to viral vectors and drug distribution in the central nervous system. This research is aimed at moving genetic therapies from lab models toward potential clinical application for rare inherited diseases.
Publication output has been relatively steady over the past decade, averaging about 8 papers per year in the last 5 years, with some year-to-year fluctuation and a recent dip in 2025 before an uptick in 2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- AAV9 gene therapy optimization for SMARD1/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model
Journal of Biomedical Science · 2026
- AAV9 gene therapy optimization for SMARD1/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model
Figshare · 2026
- AAV9 gene therapy optimization for SMARD1/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model
Figshare · 2026
- Additional file 1 of AAV9 gene therapy optimization for SMARD1/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model
Open MIND · 2026
- Additional file 1 of AAV9 gene therapy optimization for SMARD1/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model
Figshare · 2026
- Optimized AAV vector enables potent therapeutic rescue of inherited glycosylphosphatidylinositol deficiency in mice
Molecular Therapy Advances · 2026
- Targeting microRNA-dependent control of X chromosome inactivation improves the Rett Syndrome phenotype
Nature Communications · 2025
- A 3D non-human primate digital model for pharmacokinetic prediction of intra-cerebrospinal fluid drug neuraxial dispersion
Fluids and Barriers of the CNS · 2025
- A 3D Non-human Primate Digital Model for Pharmacokinetic Prediction of Intra-Cerebrospinal Fluid Drug Neuraxial Dispersion
Research Square · 2025
- The postnatal injection of AAV9-FOXG1 rescues corpus callosum agenesis and other brain deficits in the mouse model of FOXG1 syndrome
Molecular Therapy — Methods & Clinical Development · 2024
- RNA helicase IGHMBP2 regulates THO complex to ensure cellular mRNA homeostasis
Cell Reports · 2024
- Editorial: The role of glial cells in neurodegeneration
Frontiers in Molecular Medicine · 2024
- Gene therapy: State of the art precision medicine
Elsevier eBooks · 2024
- Contributors
Elsevier eBooks · 2024
- Early postnatal administration of an AAV9 gene therapy is safe and efficacious in CLN3 disease
Frontiers in Genetics · 2023
- Neurology×10
- Molecular Therapy — Methods & Clinical Development×5
- Neuromuscular Disorders×5
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Molecular Therapy×4
- Sara K. Custer
Medicine · Indiana University
- Richard Shell
Medicine · The Ohio State University
- Anton J. Blatnik
Medicine · The Ohio State University
- Arthur H.M. Burghes
Medicine · The Ohio State University
- Matthew E.R. Butchbach
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile